Global Non-24-Hour Sleep-Wake Disorder Drug Market By Indication (Circadian Rhythm Sleep Disorder, Hypernychthemeral Syndrome, Shift Work Disorder, Jet Lag and Others), Treatment Type (Therapeutic Devices, Drugs and Others), Drugs (Nonbenzodiazepines, Benzodiazepines and Others), Route of Administration (Oral, Injectable and Others), End Users (Hospitals, Home Care Settings, Specialty Clinics, Wellness Centers and Spa and Others), Distribution Channel (Retail Pharmacies, Drug Stores, Online Pharmacies and Others), Country (U.S., Canada, Mexico, Peru, Brazil, Argentina, Rest of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia Pacific, South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa) Industry Trends and Forecast to 2028
Market Analysis and Insights of Non-24-Hour Sleep-Wake Disorder Drug Market
Data Bridge Market Research analyses that the non-24-hour sleep-wake disorder drug will exhibit a CAGR of around 5.2% for the forecast period of 2021-2028. Rising government policies and initiatives to offer a fund to many research institute and pharmaceuticals companies, increasing prevalence of circadian rhythm sleep disorder cases worldwide, increase demand of disease specific treatment, and increased expenditure for the development of healthcare infrastructure are the major factors attributable to the growth of non-24-hour sleep-wake disorder drug market.
Non-24 hour sleep-wake disorder is caused by abnormalities in the suprachiasmatic nucleus. It is a condition of circadian rhythm sleep disorder that is more prevalent in blind individuals.
Rising awareness about the treatment is a major factor fostering the growth of non-24-hour sleep-wake disorder drug market. Rising expenditure on the development of healthcare infrastructure and rising personal disposable income is also fostering the growth of the non-24-hour sleep-wake disorder drug market. Also, rising of sleep disorder cases coupled with ever-rising blind population will create lucrative non-24-hour sleep-wake disorder drug market growth opportunities. Change in shifts of working associated with night shifts will also carve the way for market growth.
However, non-favourable reimbursement scenario in the developing and under developed economies will pose a major challenge to the non-24-hour sleep-wake disorder drug market growth. Preference for non-pharmacological therapies over pharmacological therapies will further challenge the market growth rate. Limited efficacy rate of available intervention will further derail the market growth rate.
This non-24-hour sleep-wake disorder drug market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on non-24-hour sleep-wake disorder drug market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Non-24-Hour Sleep-Wake Disorder Drug Market Scope and Market Size
The non-24-hour sleep-wake disorder drug market is segmented on the basis of indication, treatment type, drugs, route of administration, end users, and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.
- On the basis of indication, the non-24-hour sleep-wake disorder drug market is segmented into circadian rhythm sleep disorder, hypernychthemeral syndrome, shift work disorder, jet lag, and others.
- On the basis of treatment type, the non-24-hour sleep-wake disorder drug market is segmented into therapeutic devices, drugs and others.
- On the basis of drugs, the non-24-hour sleep-wake disorder drug market is segmented into nonbenzodiazepines, benzodiazepines, and others.
- On the basis of route of administration, the non-24-hour sleep-wake disorder drug market is segmented into oral, injectable, and others.
- On the basis of end users, the non-24-hour sleep-wake disorder drug market is segmented into hospitals, homecare settings, specialty clinics, wellness centers and spas and others.
- On the basis of distribution channel, the non-24-hour sleep-wake disorder drug market is segmented into retail pharmacies, drug stores, online pharmacies and others.
Non-24-Hour Sleep-Wake Disorder Drug Market Country Level Analysis
The non-24-hour sleep-wake disorder drug market is analysed, and market size insights and trends are provided by country, indication, treatment type, drugs, route of administration, end users, and distribution channel as referenced above.
The countries covered in the non-24-hour sleep-wake disorder drug market report are U.S., Canada, and Mexico in North America, Peru, Brazil, Argentina, and Rest of South America as part of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).
North America dominates the non-24-hour sleep-wake disorder drug market owing to the prevalence of advanced healthcare infrastructure and rising prevalence of sleep disorders. Asia-Pacific is projected to score highest growth rate and exhibit the highest CAGR for the forecast period. This is because of the rising expenditure to develop healthcare infrastructure, rising blind population and rising awareness about the treatment options.
The country section of the non-24-hour sleep-wake disorder drug market report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as consumption volumes, production sites and volumes, import export analysis, price trend analysis, cost of raw materials, down-stream and upstream value chain analysis are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs, and trade routes are considered while providing forecast analysis of the country data.
Patient Epidemiology Analysis
Non-24-hour sleep-wake disorder drug market also provides you with detailed market analysis for patient analysis, prognosis, and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Competitive Landscape and Non-24-Hour Sleep-Wake Disorder Drug Market Share Analysis
The non-24-hour sleep-wake disorder drug market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related to non-24-hour sleep-wake disorder drug market.
The major players covered in the non-24-hour sleep-wake disorder drug market report are Clinigen Group plc., Pfizer Inc., VANDA PHARMACEUTICALS, Jazz Pharmaceuticals, Inc., Jamieson Laboratories Ltd., NOW Foods, Nature’s Bounty., ALEXZA, Eisai Co., Ltd., Dr. Reddy’s Laboratories Ltd., Zydus Cadila., Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited., Johnson & Johnson Services, Bristol-Myers Squibb Company, Medtronic, Bayer AG, AbbVie Inc., and Boehringer Ingelheim International GmbH among other domestic and global players. Market share data is available for Global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA), and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
SKU-